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During the last decade, several articles have reported a relationship between advanced
age and changes in the integrity of the blood-brain barrier (BBB). These changes
were manifested not only in the morphology and structure of the cerebral microvessels
but also in the expression and function of the transporter proteins in the luminal and
basolateral surfaces of the capillary endothelial cells. Age-associated downregulation
of the efflux pumps ATP-binding cassette transporters (ABC transporters) resulted in
increased permeability and greater brain exposure to different xenobiotics and their
possible toxicity. In age-related neurodegenerative pathologies like Alzheimer’s disease
(AD), the amyloid-β (Aβ) clearance decreased due to P-glycoprotein (P-gp) dysfunction,
leading to higher brain exposure. In stroke, however, an enhanced P-gp function was
reported in the cerebral capillaries, making it even more difficult to perform effective
neuroprotective therapy in the infarcted brain area. This mini-review article focuses on
the efflux functions of the transporters and receptors of the BBB in age-related brain
pathologies and also in healthy aging.
Keywords: blood-brain barrier, aging, efflux transporters, P-glycoprotein, BCRP, Alzheimer’s disease, Parkinson’s
disease, stroke
INTRODUCTION
The blood-brain barrier (BBB) is a defensive structure and mechanism of the cerebral
capillaries which works against chemical and microbial agents which could endanger the
finely-regulated brain homeostasis (Erdo˝ et al., 2017). The most important elements of the BBB
are the capillary endothelial cells, which are connected by tight junctions (TJs) and adherens
junctions (AJ) and surrounded by the basal membrane (Ceafalan et al., 2019), pericytes, and
astrocyte endfeet. The paracellular transport of xenobiotics is blocked by occludin, claudin, and
junctional adhesion molecule (JAM) proteins, connected to zonula occludens (ZO) proteins
1, 2, and 3, respectively. The AJ proteins (nectin and cadherins) also play an important
role in the blockade of intercellular transport. The efflux transporter proteins expressed on
the luminal surface of endothelial cells (Figure 1) amplify the protection provided by the
compact cellular layers of brain microvessels and regulates the transcellular transport. These
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proteins transport their substrates against the concentration
gradient back into the cerebral circulation and this way they can
protect the brain parenchyma from dangerous molecules.
The BBB mediates a bidirectional transport of molecules
(Figure 1). For small molecules, the major players are
the transporters/carriers. For larger molecules such as
peptides, receptor mediated pathways also contribute to
transport (Figure 1).
This process is affected by aging. Both the expression level and
the functionality of ATP binding cassette transporter proteins
(ABC transporters) go through a transformation in aged subjects
under both physiological and pathological conditions. The data
in the literature available on these transformations are briefly
summarized in this article. Paracellular permeability is also
affected by physiological and pathological aging. Since it has been
covered in detail in recent reviews (Storck et al., 2018), however,
it is not covered in the present review article.
EFFLUX FUNCTIONS IN BRAIN
MICROVESSELS
In Abcb1a/Mdr1a knockout mice, brain concentration of
Mdr1a substrate ivermectin increased 87-fold, while plasma
concentration increased only 3.3-fold (Schinkel et al., 1994).
This increase of ivermectin brain exposure showed the pivotal
importance of Abcb1a in the BBB and was in good agreement
with the 50–100-fold increase in neurotoxicity of the drug
(Schinkel et al., 1994). ABCB1/Abcb1a is localized in the luminal
membrane of the BBB endothelial cells (Roberts et al., 2008). As
it displays a broad substrate specificity, it provides significant
protection to the brain.
ABCG2/BCRP/Abcg2/Bcrp1 is another luminally localized
efflux transporter thought to play a major role in protecting
the brain against toxicants. ABCG2/Abcg2 and ABCB1/Abcb1a
have overlapping substrate specificities and thus may provide
dual protection against toxicants, as shown by studies utilizing
knockout mice (Agarwal et al., 2011). In double knockouts
brain exposure to a substrate drug has often been found
>10-fold greater than brain exposure in wild type animals,
and a synergistic effect has been suggested. A detailed kinetic
analysis of Abcb1a and Abcg2 function has shown that
double knockouts over-predict drug-induced inhibition of both
transporters, as clinically relevant concentrations of perpetrators
are not likely to yield complete inhibition of ABCB1 and
ABCG2 (Kalvass et al., 2013). Complete consensus on the
potential risk of ABCB1 and ABCG2-mediated drug-drug
interaction at the BBB has still not been reached, as it
has been claimed that for victim drugs (such as several
antivirals with high-fraction transported values), a potential
for a clinically significant increase in brain exposure may
occur (Prasad and Unadkat, 2015). It is also of note that
ABCB1 inhibition yielded greater increases in brain distribution
of dual substrate [11C]tariquidar in patients carrying one
copy of the functionally impaired allele (c.421CA genotypes)
of ABCG2 than in wild-type patients (c.421CC genotype;
Bauer et al., 2016b). ABCB1 and ABCG2 cover a broad
substrate specificity range. In addition to hydrophobic substrates,
ABCB1 transports cationic drugs and ABCG2 transports many
acidic drugs (Sedykh et al., 2013).
ABCC4/MRP4/Abcc4/Mrp4 is the third major efflux
transporter expressed in the BBB (Table 1). Localization of
ABCC4 is somewhat ambiguous as it was shown to be expressed
in both the luminal and abluminal membranes of the BBB
endothelium of the bovine brain microcapillary endothelium
(Zhang et al., 2004). In contrast, in humans, it has only
been detected in the luminal membrane (Nies et al., 2004).
ABCC4 preferentially transports amphiphilic anions such as
prostaglandins, steroid and bile salt metabolites, and drugs such
as Ro-64-0802 the pharmacologically active form of oseltamivir
(Ose et al., 2009).
Quantifiable expression of ABCA2 and ABCA8 in the BBB
endothelial cells has been also reported (Table 1). ABCA2 is an
endolysosomal protein and plays a pivotal role in the homeostasis
of various lipids (Davis and Tew, 2018). As such, it has been
linked to Alzheimer’s disease (AD; Davis, 2015). ABCA8 is also
a lipid transporter and has been implicated in various brain
pathologies (Jha et al., 2019). The location of ABCA8 in the
BBB is not known. It is sinusoidally localized in hepatocytes
(Sasaki et al., 2018).
Lipoprotein receptor-related protein-1 (LRP-1) also
contributes to brain efflux of amyloid-β (Aβ) peptide
(Shibata et al., 2000). Therefore, it is often discussed along
with ABCB1 with regard AD and aging (Osgood et al., 2017).
A strong expression of the protein in the abluminal membrane
has been reported in both rats (Osgood et al., 2017) and mice
(Ma et al., 2018; Storck et al., 2018).
Among efflux transporter proteins quantified by proteomics,
Abcb1a is the most abundant in rats and mice (Table 1). In
monkeys as well as dogs, ABCG2/Abcg2 is significantly more
abundant, and in humans, the expression of the two transporters
is close to the same (Table 1). Therefore, it is likely that the
dominant role of Abcb1a over Abcg2 shown in mice (Kodaira
et al., 2010) would not directly translate into humans.
Small regional differences in transporter expression have
also been observed. The human expression of ABCG2 and
ABCB1 was about 40% greater in the occipital lobe than in the
parietal lobe (Billington et al., 2019). In the canine brain, regional
differences in Abcg2 protein expression levels were reported for
the cerebellum and the brain stem (Braun et al., 2017).
The abundance of ABCB1 was lower in men than in
women (Billington et al., 2019). This, however, did not lead
to a statistically significantly greater brain distribution of
ABCB1 substrate [11C]verapamil (Sasongko et al., 2005).
METHODS OF STUDYING EFFLUX
TRANSPORTER EXPRESSION AND
FUNCTION IN THE BBB
Early on, gene expression was studied at the mRNA level
by qRT-PCR (Osgood et al., 2017; Bors et al., 2018).
Expression testing by western blot was also common
(Rosati et al., 2003; Osgood et al., 2017; Bors et al., 2018).
Immunohistochemistry provides localization data and has been
Frontiers in Aging Neuroscience | www.frontiersin.org 2 July 2019 | Volume 11 | Article 196
Erdo˝ and Krajcsi Efflux Transporter at the Aging BBB
FIGURE 1 | Major transport pathways at the blood-brain barrier (BBB). Transcellular transport occurs by passive diffusion or is mediated by influx and efflux
transporters/carriers and/or receptors (Rec). Passive diffusion can be bidirectional; however, it is most often a blood-to-brain transport utilized by intermediate/high
passive-permeability drugs. Paracellular transport is only significant for small compounds (MW <250 Da).
frequently used despite challenges in quantitation of the data.
The contemporary approach is quantitative LC-MS/MS-based
proteomics (Table 1).
To study efflux transporter function in rodents, microdialysis
(Sziráki et al., 2011, 2013; Bors et al., 2018) and SPECT imaging
(Bors et al., 2018) has been utilized. Quinidine is the typical
ABCB1 probe for microdialysis studies (Sziráki et al., 2011,
2013; Bors et al., 2018), and applicability of (99mTechnetium)-
2-methoxy-isobutyl-isonitrile (MIBI) as an ABCB1 probe in
SPECT studies has been demonstrated (Bors et al., 2018).
With the advent of position-emission computed tomography
(PET-CT), functional testing of efflux transporters in the human
BBB has become common (Toornvliet et al., 2006; Bartels
et al., 2009; Bauer et al., 2009; Syvänen and Eriksson, 2013;
Liow et al., 2016). [11C]Verapamil has been the ABCB1/P-
glycoprotein (P-gp) selective probe substrate most commonly
used in the studies and the applicability of [11C]Loperamide as
well as [11C]Desmethylloperamide has also been demonstrated
(Syvänen and Eriksson, 2013). Probes such as [11C]Elacridar
and [11C]Tariquidar are dual substrates of ABCB1 and ABCG2
(Syvänen and Eriksson, 2013; Bauer et al., 2016a), and
[18F]FCWAY is transported by ABCB1, ABCG2 and ABCC1
(Liow et al., 2016).
EXPRESSION OF EFFLUX PATHWAYS
UPON PHYSIOLOGICAL AGING
Expression and functional studies show a nice correlation
between ABCB1 expression and function, as both show a
decrease with physiological aging (Toornvliet et al., 2006; Bartels
et al., 2009; Billington et al., 2019). Data on the effect of
aging on expression of efflux transporters in humans has
come from studies on postmortem tissue (Billington et al.,
2019). Functional studies are more frequent, where PET-CT is
used. One study in humans has shown gender specificity, as
decreased function was seen only in men (van Assema et al.,
2012). In dogs, a 72% drop in ABCB1 expression in animals
older than 100 months over animals in the 23–36 month age
group has been reported (Pekcec et al., 2011). A decrease in
Abc1a expression and function in rats has also been reported
(Rosati et al., 2003).
Data generated on SAMP8 in senescence-accelerated mice
have shown increased expression of Abcb1a (Wu et al., 2009).
However, data on BBB permeability is controversial in these
animals, as increased permeability (Ueno et al., 1993; Pelegrí
et al., 2007) and the lack of increase (Banks et al., 2000) have
both been reported. Increase in Abcb1a expression would lead
to an increased function that would be counterintuitive with
increased permeability. As data in all species but mice have
shown a decreased ABCB1 expression and function with age it
is tempting to suggest that it is a general phenomenon across
species and mice is not a good model for humans or accelerated
aging does not correctly model all aspects of physiological aging.
ABCG2/BCRP is the other major efflux transporter luminally
expressed in BBB endothelial cells, but no data have been
reported on the effect of physiological aging on BCRP expression
and/or function in the BBB. Changes in liver expression of
ABCG2 upon aging have been studied, where no difference in
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mRNA levels but a decreased expression at the protein level has
been shown (Riches et al., 2015).
In a rat model of aging, LRP1 expression on the basal surface
of the BBB endothelium was robust in 3-month-old animals, but
significantly reduced in 34-month-old animals (Osgood et al.,
2017). A reduction in LRP1 mRNA levels in cerebral microvessels
was also demonstrated in the same study.
MECHANISM OF REGULATION OF
TRANSPORTER EXPRESSION IN AGING
The studies aiming to explore the mechanism of
ABCB1 expression in humans have almost unanimously shown
decreased protein expression and function in aging (see previous
section for details). Levels of ABCB1 mRNA, however, have
not always showed a decrease with age within the same study
(Chiu et al., 2015).
In rats, the one study that covered Abcb1a expression at the
level of both mRNA and protein found a parallel decrease in
the two functions (Osgood et al., 2017). In the SAMP8 mice,
Abcb1a mRNA levels increased more significantly than Abcb1a
protein levels (Wu et al., 2009), but applicability of that
model is questionable as this is the only model that shows
an increased protein expression upon physiological aging (see
previous section for details).
One study has addressed the mechanism of down-regulation
of ABCB1. However, since patients with AD were also included
in that study (Hartz et al., 2018), it is difficult to draw conclusions
on the mechanism of the decrease of ABCB1 protein upon
only physiological aging. In humans with AD, the levels of
ubiquitination was greater than in age-matched cognitively
normal humans (Hartz et al., 2018). Increased ubiquitination was
also observed in transgenic human amyloid precursor protein
(hAPP)-overexpressing mice (Tg2576) in the same study. It was
also shown that PYR41, a cell-permeable, irreversible inhibitor
of the ubiquitin-activating enzyme E1 inhibited ubiquitination,
counteracted the decrease of Abcb1a and reduced Aβ plaque
formation in the transgenic mice. Importantly, no decrease of
LRP-1 activity in hAPP mice was observed (Hartz et al., 2018).
EFFLUX PUMPS AT THE BBB IN
AGE-RELATED PATHOLOGICAL
CONDITIONS
Aged people are at higher risk of medicine-induced toxicities
resulting from either increased drug sensitivity or age-related
pharmacokinetic changes. The situation is further complicated
with the two most prevalent age-related neurodegenerative
diseases, AD and Parkinson’s disease (PD), for both of which
there is growing evidence of altered structure and function of
the BBB, including downregulation of TJ proteins and efflux
transporters such as P-gp (Bors et al., 2018). These alterations
would have an impact on CNS drug exposure and the risk of
neurotoxicity from systemically-acting drugs (Erdo˝ et al., 2017;
Pan and Nicolazzo, 2018). Qosa et al. (2016) have summarized
the directions of the efflux transporter alterations at the BBB in
different neurodegenerative disorders. They showed that P-gp
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is downregulated in AD, Creutzfeldt-Jakob syndrome, multiple
sclerosis, brain tumors, PD, and schizophrenia, while it is
upregulated in amyotrophic lateral sclerosis, epilepsy, stroke, and
ischemic brain injuries. There are many unanswered questions
about the role of BCRP, MRP1, and MRP2 in neurodegenerative
diseases (Qosa et al., 2016). In the next paragraphs only the three
most important examples are shown in more details.
Alzheimer’s Disease
The involvement of transporters located at the BBB has been
suggested in the control of cerebral Aβ levels, and thereby in
AD. Active transport of Aβ across the BBB seems to involve
a number of transporters that control the level of the soluble
isoform of Aβ in brain. P-gp contributes to the efflux of
brain-derived Aβ into blood (Kuhnke et al., 2007; Bell and
Zlokovic, 2009; Hartz et al., 2010; Brenn et al., 2011; Vogelgesang
et al., 2011; Sagare et al., 2012; Sharma et al., 2012; Erdo˝
et al., 2017). It seems that, in addition to the age-related
decrease of P-gp expression, Aβ1–42 itself downregulates the
expression of P-gp and other Aβ transporters, which could
exacerbate the intracerebral accumulation of Aβ and thereby
accelerate neurodegeneration in AD and cerebral Aβ angiopathy.
Systemic inflammation by lipopolysaccharide triggers defects
in P-gp-mediated Aβ clearance from the brain and leads to
its accumulation (Ravenstijn et al., 2008). Reduction of P-gp
expression and transport activity has been found in isolated
capillaries as a result of Aβ40 mediated P-gp ubiquitination,
internalization, and proteasome-dependent degradation (Hartz
et al., 2016). However, little is known about the regulation of
these transporters at the BBB (Do et al., 2016) in animal models
of AD. The most efficient therapeutic strategy for limiting the
accumulation of Aβ in the brain as early as possible in disease
development could be to block Aβ influx by inhibiting Rage
and/or Oatp1a4, or to stimulate the synthesis and/or function of
Abca1 and/or Abcg4 at the BBB (Do et al., 2016).
Parkinson’s Disease
The brain distribution of compounds with different transport
mechanisms across the BBB (l-3,4-dihydroxyphenylalanine,
carbamazepine, quinidine, lovastatin, and simvastatin) in healthy
and MPTP-treated macaques have been studied. Thiollier et al.
(2016) found only changes in the distribution of quinidine,
indicating changes in P-gp functionality. In contrast, studies
performed by Hou et al. (2014) suggest that P-gp inhibition
increases BBB permeability to N-[2-(4-hydroxy-phenyl)-ethyl]-
2-(2,5-dimethoxyphenyl)-3-(3-methoxy-4-hydroxy-phenyl)-
acrylamide (FLZ), a novel synthetic squamosamide derivative
and potential anti-PD agent. No significant differences were
observed, however, in the brain distribution of FLZ between
normal and PD model rats, suggesting no significant change in
P-gp in PD (Hou et al., 2014). Bartels et al. (2008a,b) investigated
in vivo BBB P-gp function in patients with parkinsonian
neurodegenerative syndromes using [11C]verapamil PET.
Advanced PD patients had increased [11C]verapamil uptake
in frontal white matter regions compared with controls. The
authors concluded that lower [11C]verapamil uptake in midbrain
and frontal regions of de novo PD patients could indicate a
regional up-regulation of P-gp function (Bartels et al., 2008b).
However, in a later study by this group, the decreased BBB
P-gp function in early-stage PD patients could not be confirmed
(Bartels et al., 2008a).
Stroke
Stroke risk increases with aging, and one-third of ischemic
strokes occur in the very elderly (> or = 80 years). These are
responsible for two-thirds of the overall stroke-related morbi-
mortality (Ly and Maquet, 2014).
Rats subjected to middle cerebral artery occlusion (MCAO)
for 90 min and killed at 4, 14, 24, and 48 h postreperfusion
onset were studied to determine the time course of P-gp
expression. To mimic ischemia occurring at the BBB, rat
brain endothelial (RBE4) cells were subjected to hypoxia
and low glucose (HLG) for 16 h. Immunoblotting analyses
showed P-gp increases in brain and liver following 90-min
MCAO, as well as in cultured RBE4 cells after 16-h HLG
treatment. The increase in P-gp could dramatically reduce
the bioavailability and efficacy of neuroprotective drugs. P-gp,
therefore, represents a big hurdle in drug delivery to the ischemic
brain (DeMars et al., 2017).
CONCLUSIONS AND OUTLOOK
Transporter proteomics has been used in the past decade to
study expression in the BBB, but mostly from a perspective
of drug exposure (Uchida et al., 2011a; Trapa et al., 2019),
and many questions on the effect of aging and disease on
efflux transporter expression and function are still open. The
physiology and pathophysiology, as well as the cell biology and
biochemistry of transport, are new fields. One uncertainty is
the correlation of expression and activity of efflux proteins. In
general, it is assumed that protein expression and activity for
ABCB1 and ABCG2 correlate (Uchida et al., 2011a; Trapa et al.,
2019). However, it is not always the case when mRNA levels and
function have been monitored (Vilas-Boas et al., 2011). In some
studies, discrepancies between protein expression and function
have also been reported (Poller et al., 2010).
It is reasonable to assume that a complex interplay of
age-related decrease and a disease-related stimulation shapes
the expression profile of efflux transporters. Indeed, a biphasic
regulation of ABCB1 in AD has been suggested (Vogelgesang
et al., 2004). Also, ABCB1 and ABCG2 expression by
neuroinflammatory stimuli displayed a complex pattern (von
Wedel-Parlow et al., 2009). Inhibition of efflux function at
the time when it plays a protective role is counterintuitive.
In contrast, the inhibition of efflux functions to enhance
the BBB permeability for drug delivery may make sense.
The time dependence of pathophysiological changes must be
pinned down to utilize the data to drive pharmaceutical and
nutraceutical research.
In addition to temporal changes, regional variance (Deo et al.,
2014; Kannan et al., 2017) in the expression of transporters is
a factor to consider. Both could be monitored with imaging.
However, [11C]verapamil is not an ideal probe for ABCB1, due
to its lipophilicity (Luurtsema et al., 2016). Development of
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novel probes or employment of drug probes used for preclinical
species could enable the scientific community to address these
issues. 18F-FCWAY is a weak substrate of ABCB1 and has been
suggested as a probe to address both up- and down-regulation of
ABCB1 transport activities (Liow et al., 2016).
Therapeutic strategies must also take into account the fact
that expression of proteins such as ABCA2 show an inverse
correlation with disease (Michaki et al., 2012). Strategies based
on the modulation of transporter expression must, therefore,
use selective inducers/repressors to provide therapeutic efficacy.
Induction of proteins that slow disease progression (e.g., ABCB1)
without induction of proteins (e.g., ABCA2) that facilitate disease
progression is one possible strategy. ABCB1 and ABCA2 display
inverse regulation upon the differentiation of colon tumors
(Ohtsuki et al., 2007). However, it remains to be tested
if agonists of the pregnane X receptor (PXR) that induce
ABCB1 expression have a favorable induction/repression profile
on transporters and receptors also involved in pathogenesis of
neurodegenerative diseases.
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